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Objectives—The purpose of this study was to estimate the efficiency of first-trimester
uterine artery Doppler, A-disintegrin and metalloprotease 12 (ADAM12), pregnancyassociated plasma protein A (PAPP-A), and maternal characteristics in the prediction
of preeclampsia.
Methods—We conducted a prospective cohort study of patients presenting for firsttrimester aneuploidy screening between 11 and 14 weeks’ gestation. Maternal serum
ADAM12 and PAPP-A levels were measured by an immunoassay, and mean uterine
artery Doppler pulsatility indices were calculated. Outcomes of interest included
preeclampsia, early preeclampsia (defined as requiring delivery at <34 weeks’ gestation), and gestational hypertension. Logistic regression analysis was used to model the
prediction of preeclampsia using ADAM12 multiples of the median (MoM), PAPPA MoM, and uterine artery Doppler pulsatility index MoM, either individually or in
combination. The sensitivity, specificity, and area under the receiver operating characteristic curves were used to compare the screening efficiency of the models using nonparametric U statistics.
Results—Among 578 patients with complete outcome data, there were 54 cases of
preeclampsia (9.3%) and 13 cases of early preeclampsia (2.2%). Median ADAM12
levels were significantly lower in patients who developed preeclampsia compared to
those who did not (0.81 versus 1.01 MoM; P = .04). For a fixed false-positive rate of
10%, ADAM12, PAPP-A, and uterine artery Doppler parameters in combination with
maternal characteristics identified 50%, 48%, and 52% of patients who developed
preeclampsia, respectively. Combining these first-trimester parameters did not improve
the predictive efficiency of the models.
Conclusions—First-trimester ADAM12, PAPP-A, and uterine artery Doppler characteristics are not sufficiently predictive of preeclampsia. Combinations of these parameters do not further improve their screening efficiency.
Key Words—A-disintegrin and metalloprotease 12; pregnancy-associated plasma protein A; placental dysfunction; preeclampsia; uterine artery Doppler sonography

P

reeclampsia affects 5% to 8% of pregnancies and remains a
substantial contributor to perinatal morbidity and mortality worldwide.1,2 Abnormal invasion of the placental trophoblast into the maternal spiral arterioles, as early as the first
trimester, is the proposed pathophysiologic mechanism for the
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development of this disorder. This abnormal placentation
results in a high-resistance uteroplacental circulation bed
and persistent placental underperfusion, leading to the
phenotype of preeclampsia.
The use of biochemical and sonographic parameters
to detect these pathologic changes and identify patients at
high risk of developing preeclampsia has been an area of
intense research focus over recent years. Prior studies have
demonstrated an association between low levels of pregnancy-associated plasma protein A (PAPP-A), a serum
analyte routinely measured as part of first-trimester aneuploidy screening, and the subsequent development of
preeclampsia later in pregnancy. However, PAPP-A alone
has demonstrated only modest predictive efficiency for
adverse pregnancy outcomes, including preeclampsia.3–6
More recent studies have evaluated the association between
low levels of a novel serum analyte, A-disintegrin and metalloprotease 12 (ADAM12), and preeclampsia and have
produced conflicting results.7–9 These studies mainly have
been limited to case-control designs performed in populations with a low prevalence of preeclampsia, and, therefore,
may have been subject to bias. In addition, these studies
have primarily been conducted in low-risk populations,
thereby precluding a rigorous evaluation of maternal risk
factors, which may increase the screening efficiency of these
biomarkers. Finally, uterine artery Doppler studies have
been proposed as screening tools to detect increased vascular resistance in patients destined to develop preeclampsia, with reported sensitivity values ranging from 7% to 80%
when performed in the first trimester.10–15
The objective of this study was to estimate the efficiency of first-trimester ADAM12, PAPP-A, uterine artery
Doppler, and maternal characteristics, both individually
and in combination, in the prediction of preeclampsia. We
hypothesized that a combination of these first-trimester
parameters, in addition to maternal clinical risk factors,
may allow for more accurate identification of women at
risk. Although there is currently no known effective strategy for the prevention of preeclampsia, the ability to predict patients at high risk of developing this disorder not
only may provide an opportunity to affect pregnancy management but also may provide an opportunity to identify
an enriched population of patients who can serve as target
patients for future interventional studies.

Materials and Methods
We conducted a prospective cohort study of patients presenting to Washington University Medical Center from
2008 to 2010 for first-trimester aneuploidy screening.
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Women with singleton pregnancies between 11 and 14
weeks’ gestation were eligible for inclusion. Exclusion criteria were known aneuploidy and major congenital malformations. Institutional Review Board approval was obtained,
and all patients provided written informed consent.
All consecutive eligible patients were approached for
participation in the study at the time of their sonographic
examinations. The standard of care for first-trimester aneuploidy screening at our institution includes fetal crownrump length measurement to confirm pregnancy dating
(within ±7 days of menstrual dating), nuchal translucency
measurement, and serum PAPP-A and free β-human
chorionic gonadotropin measurements. Serum PAPP-A
and free β-human chorionic gonadotropin measurements
are routinely performed by Perkin Elmer Laboratories
(Melville, NY) for all samples collected at our institution.
Patients who consented to study participation provided an
additional 10 mL of blood, which was used to measure the
ADAM12 concentration. Maternal blood was collected
into nonheparinized tubes and centrifuged at 1500g for 15
minutes. Maternal serum was then extracted and stored at
–80°C until analyzed. A 25-μL aliquot of maternal serum
was used to determine the ADAM12 concentration by a
time-resolved fluorescent immunoassay, in which the concentration of ADAM12 was directly proportional to the fluorescence measured at 615 nm (DELFIA/AutoDELFIA
ADAM12 research kit; PerkinElmer Life and Analytical
Sciences, Turku, Finland). All serum analyte levels were
converted into multiples of the median (MoM), adjusted
for gestational age, for analysis.
Patients who consented to the study also underwent
bilateral uterine artery Doppler assessment. This assessment was performed by a transabdominal approach with
color flow mapping. A midsagittal view of the uterus was
obtained, and the cervical canal was identified. The transducer was then rotated until the paracervical vessels were
identified. Each uterine artery was then isolated, and the
pulsatility index (PI) was measured and averaged. These
measurements were also converted into MoM, adjusted
for gestational age. All participating sonographers were certified by the Fetal Medicine Foundation for first-trimester
Doppler measurements.
Maternal demographics, medical histories, and obstetric histories were obtained from a detailed questionnaire
routinely administered at the time of all initial sonographic
examinations in our unit. Delivery outcome information
was obtained from an electronic medical record review by
a dedicated nurse coordinator. Patients who delivered outside our institution signed a consent for release of medical
records at the time of study enrollment.

J Ultrasound Med 2013; 32:1593–1600
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The primary outcome for this study was preeclampsia,
defined as systolic blood pressure higher than 140 mm Hg
or diastolic blood pressure higher than 90 mm Hg on at
least 2 occasions separated by at least 4 hours in the presence of proteinuria (≥0.3 g in a 24-hour specimen or ≥1+
protein on a urine dipstick) after 20 weeks’ gestation. Secondary outcomes included early preeclampsia, defined as
preeclampsia requiring delivery before 34 weeks, and gestational hypertension, defined as blood pressure higher
than 140/90 mm Hg in the absence of proteinuria after 20
weeks’ gestation.1,16
Baseline maternal characteristics as well as ADAM12,
PAPP-A, and uterine artery PI MoM values were compared between patients who developed preeclampsia and
those who did not. Categorical variables were compared
by χ2 tests, and continuous variables were compared by an
independent samples t test and the Mann-Whitney U test,
as appropriate. Normality of distribution was evaluated by
the Kolmogorov-Smirnov test. Logistic regression was
then used to model the prediction of preeclampsia, incorporating various combinations of first-trimester parameters as well as maternal factors identified as significant in
the univariate analysis. There was no evidence of colinearity between the first-trimester parameters and maternal
characteristics of interest, thereby justifying their inclusion
together in the various models. Receiver operating characteristic curves were generated for each model, and the
area under the curve (AUC) was compared between each
model by nonparametric U statistics. Sensitivity and
specificity values at both 10% and 20% fixed false-positive
rates were also calculated for each model. P < .05 was
considered statistically significant. All statistical analyses
were performed with STATA 12 Special Edition software
(StataCorp, College Station, TX).
Since the focus of this study was on the development
of a highly sensitive prediction model for preeclampsia, the
precision of our sample size estimates was based on the
half-width of the 95% confidence interval (CI) and the
incidence of preeclampsia in our patient population. With
these assumptions, our study was powered to produce a
prediction model with 70% sensitivity (95% CI, 57%–83%)
for preeclampsia and 90% sensitivity (95% CI, 75%–
100%) for early preeclampsia.

Results
Of 618 patients enrolled, 13 were lost to follow-up, and 3
withdrew from the study before completion. After excluding patients who underwent spontaneous abortion (n = 8)
or elective abortion (n = 1) and those with incomplete out-

J Ultrasound Med 2013; 32:1593–1600

come information (n = 15), 578 patients were available for
analysis, constituting our final study cohort. Of these
patients, 54 (9.3%) developed preeclampsia, 13 (2.2%)
developed early preeclampsia, and 55 (9.5%) developed
gestational hypertension. The mean gestational age ± SD
at the time of sonography and study enrollment was 12.1
± 0.6 weeks. Compared to patients who did not develop
preeclampsia, patients who went on to develop preeclampsia were more likely to be African American, have a higher
prepregnancy body mass index, and have a higher incidence of both chronic hypertension and pregestational diabetes (Table 1).
Patients who developed preeclampsia had significantly lower ADAM12 levels (0.81 versus 1.01 MoM; P =
.04) and PAPP-A levels (0.88 versus 1.18 MoM; P < .001)
compared to controls; however, there was no significant
difference in uterine artery Doppler PI levels in preeclamptic patients compared to controls (1.00 versus 0.99 MoM;
P = .77). There was no significant difference in ADAM12,
PAPP-A, or uterine artery Doppler PI levels when comparing patients who developed early preeclampsia or gestational hypertension to those who did not (Table 2).
Individually, ADAM12, PAPP-A, and uterine artery
Doppler parameters were not sufficiently predictive of
preeclampsia, resulting in AUCs ranging from 0.49 to 0.64.
In fact, maternal characteristics alone (AUC, 0.78; 95% CI,
0.71–0.75) were significantly more predictive of preeclampsia than any first-trimester parameter alone (ADAM12
alone, P < .001; PAPP-A alone, P = .01; uterine artery
Doppler alone, P < .001). Combining these first-trimester
parameters with maternal characteristics did improve the
predictive efficiency of the models. The best overall predictive efficiency was observed with the combination of
maternal characteristics, ADAM12, PAPP-A, and uterine
Table 1. Baseline Maternal Characteristics and Obstetric History
Characteristic

Preeclampsia
(n = 54)

Control
(n = 524)

Maternal age, ya

30.2 ± 6.1

31.3 ± 5.8

Race, %
White
African American
Hispanic
Asian
Other
Body mass index, kg/m2a
Nulliparity, %
Tobacco use, %
Chronic hypertension, %
Pregestational diabetes, %

42.6
48.1
0
5.6
3.7
34.0 ± 9.2
20.4
13.2
38.9
22.2

57.4
28.1
2.6
9.0
2.9
28.1 ± 7.4
27.5
8.7
6.7
5.6

P
.23
.03

<.001
.26
.27
<.001
<.001

aData are expressed as mean ± SD.
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artery Doppler parameters, with an AUC of 0.79 (95% CI,
0.71–0.87) and sensitivity values of 50% and 75% at 10%
and 20% false-positive rates, respectively. However, this
predictive efficiency still was not statistically different from
that of the model containing maternal characteristics alone
(P = .77; Table 3). The significant independent predictors
of preeclampsia in this model included PAPP-A, body
mass index, history of chronic hypertension, and history of
pregestational diabetes.
Similar results were observed for the prediction of
early preeclampsia and gestational hypertension. The
ADAM12, PAPP-A, and uterine artery Doppler parameters alone were not predictive of the development of early
preeclampsia or gestational hypertension. Combining
these parameters with maternal risk factors did improve
the predictive efficiencies; however, models containing the
first-trimester parameters did not differ significantly from
those containing maternal characteristics alone. The best
overall predictive efficiency for early preeclampsia was
observed with the combination of maternal characteristics,
ADAM12, and PAPP-A, with an AUC of 0.78 (95% CI,

Table 2. Comparison of First-Trimester Marker Levels Between Study
Groups
Marker
ADAM12 MoM
PAPP-A MoM
Uterine artery
Doppler PI MoM
Marker
ADAM12 MoM
PAPP-A MoM
Uterine artery
Doppler PI MoM

Marker
ADAM12 MoM
PAPP-A MoM
Uterine artery
Doppler PI MoM

Preeclampsia
(n = 54)
0.81
(0.61–1.30)
0.88
(0.62–1.27)
1.00
(0.85–1.22)

Control
(n = 524)

1.01
.04
(0.74–1.36)
1.18
<.001
(0.60–1.63)
0.99
.77
(0.79–1.23)

Early Preeclampsia Control
(n = 13)
(n = 565)
0.82
(0.57–1.21)
1.02
(0.73–1.53)
1.00
(0.79–1.22)
Gestational
Hypertension
(n = 55)
0.81
(0.63–1.22)
1.18
(0.82–1.73)
0.96
(0.78–1.13)

1.00
(0.73–1.35)
1.14
(0.76–1.58)
1.00
(0.89–1.43)
Control
(n = 523)
1.01
(0.73–1.35)
1.13
(0.76–1.58)
1.01
(0.80–1.24)

Data are expressed as median (interquartile range).
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P

P
.11

0.63–0.93) and sensitivity values of 54% and 62% at 10%
and 20% false-positive rates, respectively (Table 4).
The best overall predictive efficiency for gestational hypertension was observed with the combination of maternal
characteristics, ADAM12, PAPP-A, and uterine artery
Doppler parameters, with an AUC of 0.66 (95% CI, 0.58–
0.74) and sensitivity values of 15% and 28% at 10% and
20% false-positive rates, respectively (Table 5). The only
significant independent predictor of early preeclampsia in
this model was a maternal history of chronic hypertension.
To evaluate the predictive indices of our model, we
created two hypothetical populations, one with a low
prevalence of disease (1%) and one with a high prevalence
of disease (10%). Using the calculated sensitivity values of
our models at a 10% false-positive rate, positive predictive
values (PPVs) and negative predictive values (NPVs) were
estimated for our models containing maternal characteristics alone as well as the combination of maternal characteristics with ADAM12, PAPP-A, and uterine artery
Doppler parameters. For the outcome of preeclampsia, the
PPV and NPV were 4.8% and 99.4%, respectively, in
the low-prevalence population and 35.7% and 94.2% in the
high-prevalence population for maternal characteristics
alone. For the outcome of early preeclampsia, the PPV and
NPV were 5.3% and 99.5% in the low-prevalence population and 37.9% and 94.7% in the high-prevalence population for maternal characteristics alone. Finally, for the
outcome of gestational hypertension, the PPV and NPV
were 1.5% and 99.0% in the low-prevalence population and
14.3% and 90.5% in the high-prevalence population for
maternal characteristics alone. When evaluating the models containing the combination of maternal characteristics
and first-trimester markers of placental dysfunction, the
predictive indices were identical to the models containing
maternal characteristics alone.

Discussion

.55
.22

P
.07
.51
.10

Findings from our prospective cohort demonstrate that
both ADAM12 and PAPP-A levels are significantly
reduced in patients who develop preeclampsia. Similar to
PAPP-A, ADAM12 is a protease for insulin-like growth
factor–binding proteins. Low levels of this analyte reflect
an increased amount of insulin-like growth factor in the
bound state, which is then unavailable to promote placental growth and development, making this finding biologically plausible.17,18 However, despite these associations,
the predictive efficiency of ADAM12 and PAPP-A was
overall modest and not sufficient for clinical use. In fact,
our findings suggest that maternal characteristics alone

J Ultrasound Med 2013; 32:1593–1600
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Table 3. Predictive Efficiency of First-Trimester Markers for Preeclampsia
Marker
Maternal characteristics alone
ADAM12 alone
PAPP-A alone
Uterine artery Doppler alone
ADAM12 + PAPP-A + uterine artery Doppler
Maternal characteristics + ADAM12
Maternal characteristics + PAPP-A
Maternal characteristics + uterine artery Doppler
Maternal characteristics + ADAM12 + PAPP-A
Maternal characteristics + ADAM12 + uterine artery Doppler
Maternal characteristics + ADAM12 + PAPP-A + uterine artery Doppler

AUC
(95% CI)
0.78
(0.71–0.85)
0.58
(0.50–0.67)
0.64
(0.57–0.72)
0.49
(0.41–0.56)
0.64
(0.57–0.72)
0.78
(0.70–0.85)
0.79
(0.72–0.86)
0.77
(0.69–0.86)
0.79
(0.71–0.86)
0.78
(0.70–0.86)
0.79
(0.71–0.87)

Sensitivity
(10% FPR), %

Sensitivity
(20% FPR), %

50

62

12

30

18

32

5

16

22

42

50

62

48

64

52

64

50

70

52

62

50

75

FPR indicates false-positive rate. Maternal characteristics included African American race, body mass index, history of chronic hypertension, and
history of pregestational diabetes.

Table 4. Predictive Efficiency of First-Trimester Markers for Early Preeclampsia
Marker
Maternal characteristics alone
ADAM12 alone
PAPP-A alone
Uterine artery Doppler alone
ADAM12 + PAPP-A + uterine artery Doppler
Maternal characteristics + ADAM12
Maternal characteristics + PAPP-A
Maternal characteristics + uterine artery Doppler
Maternal characteristics + ADAM12 + PAPP-A
Maternal characteristics + ADAM12 + uterine artery Doppler
Maternal characteristics + ADAM12 + PAPP-A + uterine artery Doppler

AUC
(95% CI)
0.71
(0.54–0.88)
0.63
(0.46–0.80)
0.55
(0.38–0.71)
0.60
(0.44–0.75)
0.65
(0.48–0.82)
0.77
(0.62–0.93)
0.75
(0.60–0.90)
0.71
(0.53–0.90)
0.78
(0.63–0.93)
0.77
(0.61–0.93)
0.77
(0.62–0.93)

Sensitivity
(10% FPR), %

Sensitivity
(20% FPR), %

55

58

22

30

16

22

10

38

35

46

54

62

54

54

54

62

54

62

54

62

54

62

FPR indicates false-positive rate. Maternal characteristics included African American race and history of chronic hypertension.

J Ultrasound Med 2013; 32:1593–1600

1597

3209jum_Layout 1 8/20/13 11:43 AM Page 1598

Goetzinger et al—ADAM12, Uterine Artery Doppler Parameters, and Preeclampsia

actually have superior test performance characteristics for
the prediction of preeclampsia, which are not enhanced by
the addition of these first-trimester markers, either individually or in combination.
Prior studies have been conflicting regarding the role
of ADAM12 in the prediction of preeclampsia. Both
Laigaard et al7 and Spencer et al8 demonstrated decreased
serum concentrations of ADAM12 in the first-trimester in
women who went on to develop preeclampsia. Consistent
with our results, Spencer et al8 also demonstrated only a
modest predictive efficiency of ADAM12 for preeclampsia,
with an AUC of 0.694 for ADAM12 alone and an AUC of
0.714 when ADAM12 and PAPP-A were combined. Alternatively, Poon et al9 found that first-trimester ADAM12
levels were not significantly lower in patients who developed preeclampsia compared to controls. They attributed
these negative findings to a priori adjustment of ADAM12
levels for race and maternal weight. When these maternal
characteristics were evaluated in our population, we found
no relationship between ADAM12 and maternal race.
Although there was a modest correlation between ADAM12
levels and maternal weight, we adjusted for this factor in
our prediction model as an established maternal clinical
risk factor for preeclampsia.

Our study did not demonstrate any significant difference
in uterine artery PI measurements between preeclamptic and
control patients. Given that maximal trophoblast invasion
occurs during the first trimester, it would seem justified that
enhanced vascular resistance in the uterine arteries would be
detectable at this early stage of gestation in patients with
impaired placentation.19 Recently, Parra-Cordero et al20
demonstrated a significant increase in the first-trimester uterine artery Doppler PI in patients who developed both earlyand late-onset preeclampsia compared to controls. In that
study, the sensitivity of the maternal history plus uterine artery
Doppler parameters for detecting early- and late-onset
preeclampsia were 43.8% and 28.3%, respectively, at a 10%
false-positive rate.20 Although our study did not demonstrate
a significant difference in absolute uterine artery PI values, the
sensitivity of maternal characteristics and uterine artery
Doppler parameters were similar to that observed by ParraCordero et al,20 at 54% and 52%, respectively, at a 10% falsepositive rate. Again, this finding suggests that the predictive
value of these first-trimester parameters may be primarily
driven by the contribution of maternal characteristics alone.
In addition, Poon et al21 demonstrated that first-trimester
uterine artery Doppler parameters were significantly increased
in patients who developed hypertensive disorders later in
pregnancy. Differences between these studies and our study

Table 5. Predictive Efficiency of First-Trimester Markers for Gestational Hypertension
Marker
Maternal characteristics alone
ADAM12 alone
PAPP-A alone
Uterine artery Doppler alone
ADAM12 + PAPP-A + uterine artery Doppler
Maternal characteristics + ADAM12
Maternal characteristics + PAPP-A
Maternal characteristics + uterine artery Doppler
Maternal characteristics + ADAM12 + PAPP-A
Maternal characteristics + ADAM12 + uterine artery Doppler
Maternal characteristics + ADAM12 + PAPP-A + uterine artery Doppler

AUC
(95% CI)
0.62
(0.55–0.70)
0.57
(0.49–0.66)
0.53
(0.44–0.61)
0.57
(0.49–0.64)
0.59
(0.52–0.66)
0.62
(0.53–0.72)
0.63
(0.55–0.71)
0.64
(0.56–0.71)
0.63
(0.54–0.73)
0.65
(0.57–0.73)
0.66
(0.58–0.74)

Sensitivity
(10% FPR), %

Sensitivity
(20% FPR), %

15

22

15

32

20

26

16

22

12

20

12

36

12

28

8

30

14

42

10

28

15

28

FPR indicates false-positive rate. Maternal characteristics included African American race and body mass index.
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may be due to the varying criteria used to define an abnormal
uterine artery Doppler PI. Both of the above-mentioned studies measured the right and left uterine artery PIs and used the
lowest recorded value in their analysis. Alternatively, our study
used the average value of the right and left uterine artery PI
measurements, a technique that has been described previously.12,14 We believe that this average value is more representative of overall placental perfusion. This discrepancy
between studies further supports the claim that first-trimester
uterine artery Doppler parameters may not be reliable predictors of preeclampsia, as we would have expected to observe
more consistent results across studies regardless of the criteria used to define an abnormal value. Furthermore, differences
in study populations as well as variability in the maternal factors included in the prediction models may also account for
some of the discrepancy observed between studies.
Strengths of our study included its prospective cohort
design and low rate of loss to follow-up. This study design
allowed us to ensure that our unaffected patients were derived
from the same population as our affected patients, thereby
eliminating the bias that is often introduced in case-control
studies through the process by which control patients are
selected. In addition, given that our study was performed in a
tertiary referral center, there was adequate representation of
maternal comorbidities, which could then be rigorously
evaluated as maternal risk factors for the development of
preeclampsia.
Our study was not without limitations. Despite our large
cohort, the small number of early preeclampsia cases (n = 13)
left us underpowered to thoroughly evaluate this outcome.
In addition, although we did adjust for gestational age, we did
not perform an a priori adjustment of ADAM12 levels for
other maternal characteristics. However, data in the literature
as well as in our own population have been conflicting as to
which factors truly have a significant effect on this analyte.
Given that these proposed adjustment factors are also wellestablished risk factors for preeclampsia, we instead took the
approach of controlling for these factors in our prediction
model to provide a more individualized risk assessment based
on maternal characteristics and history. Furthermore, our
medical center is a high-risk tertiary referral center, which
likely contributed to the high prevalence of preeclampsia in
our study population; however, this high prevalence of
preeclampsia should not have affected the overall accuracy of
our prediction model, given that sensitivity and specificity are
independent of prevalence. Finally, the methods used in this
study were aimed at population-based screening for hypertensive disorders in pregnancy. These risk factors may still
play a substantial role in individualized patient risk assessment
and counseling.

J Ultrasound Med 2013; 32:1593–1600

In conclusion, our study demonstrates that although
first-trimester ADAM12 and PAPP-A levels are significantly reduced in patients who develop preeclampsia, the
predictive efficiency of these first-trimester serum markers
as well as uterine artery Doppler studies, both individually
and in combination, are not superior to that achieved by
maternal characteristics alone. Continued investigation of
novel serum and sonographic markers of placental dysfunction is warranted to more accurately identify this highrisk population.
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